Cancer pharmacogenomics may require both qualitative and quantitative approaches

Cell Cycle

Volumn 4, Issue 11, 2005, Pages 1506-1509

  Cheng, Qing ^a   Evans, William E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Amplification; Aneuploidy; Cancer pharmacogenomics; Chromosomal abnormality; Genetic polymorphisms; Karyotype; Loss of heterozygosity; Pharmacogenetics; Quantitative allele specific genotyping; Structure variation

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FLUOROURACIL; GENOMIC DNA; MESSENGER RNA; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER MORTALITY; CARCINOGENESIS; CARCINOMA; CHILDHOOD CANCER; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE AMPLIFICATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOMICS; GENOTYPE; HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUANTITATIVE GENETICS; REVIEW; STATISTICAL SIGNIFICANCE; TOXICOGENETICS;

EID: 27744572337     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.11.2160     Document Type: Review

References (53)

1. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429:464-8.
2. Evans WE, Mcleod HI. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-49.
3. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19:2293-301.
4. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2:331-41.
5. Issa JP. Cpg island methylator phenotype in cancer. Nat Rev Cancer 2004; 4:988-93.
6. Baak JP, Path FR, Hermsen MA, Meijer G, Schmidt J, Janssen EA. Genomics and proteomics in cancer. Eur J Cancer 2003; 39:1199-215.
7. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339:605-15.
8. Cheng Q, Yang W, Raimondi SC, Pui CH, Relling MV, Evans WE. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 2005; 37:878-82.
9. Mcleod HI, Marsh S. Pharmacogenetics Goes 3D. Nat Genet 2005; 37:794-5.
10. Albertson DG, Collins C, Mccormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet 2003; 34:369-76.
11. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004; 432:338-41.
12. Paulsson K, Panagopoulos I, Knuutila S, et al. Formation of trisomies and their parental origin in hyperdiploid childhood acute lymphoblastic leukemia. Blood 2003; 102:3010-5.
13. Rivera GK, Zhou Y, Hancock MI, et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 2005; 103:368-76.
14. Wilson JI, Morison IM. No evidence for preferential maternal origin of duplicated chromosome 14 in hyperdiploid ALL. Blood 2005; 105:1837.
15. Masuda A, Takahashi T. Chromosome instability in human lung cancers: Possible underlying mechanisms and potential consequences in the pathogenesis. Oncogene 2002; 21:6884-97.
16. Draviam VM, Xie S, Sorger PK. Chromosome segregation and genomic stability. Curr Opin Genet Dev 2004; 14:120-5.
17. Duesberg P, Li R, Rasnick D. Aneuploidy approaching a perfect score in predicting and preventing cancer: Highlights from a conference held in Oakland, CA in January, 2004. Cell Cycle 2004; 3:823-8.
18. Guan XY, Meltzer PS, Dalton WS, Trent JM. Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome micro dissection. Nat Genet 1994; 8:155-61.
19. Jarmuz M, Grenman R, Golusinski W, Szyfter K. Aberrations of 11q13 in laryngeal squamous cell lines and their prognostic significance. Cancer Genet Cytogenet 2005; 160:82-8.
20. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E. Her2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 2001; 12:S15-9.
21. Scholl S, Beuzeboc P, Pouillart P. Targeting Her2 in other tumor types. Ann Oncol. 2001; 12:581-7.
22. Leyland-Jones B. Trastuzumab: Hopes and realities. Lancet Oncol 2002; 3:137-44.
23. Tanner M, Hollmen M, Junttila TT, et al. Amplification of Her-2 in gastric carcinoma: Association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16:273-8.
24. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIalpha associate with Erbb-2 amplification and affect sensitivity to topoisomerase Ii inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156:839-47.
25. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase Iialpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8:1001-7.
26. Wang TI, Diaz Jr La, Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 2004; 101:3089-94.
27. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57:314-9.
28. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335:1041-8.
29. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80.
30. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell 2003; 3:51-62.
31. Yasui K, Mihara S, Zhao C, et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 2004; 64:1403-10.
32. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: A novel mechanism for MDR-1 gene activation. J Clin Invest 1997; 99:1947-57.
33. Chen GK, Lacayo NJ, Duran GE, et al. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma. Genes Chromosomes Cancer 2002; 34:372-83.
34. Gupta PK, Sahota A, Boyadjiev SA, et al. High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination. Cancer Res. 1997; 57:1188-93.
35. Grundei T, Vogelsang H, Ott K, et al. Loss of heterozygosity and micro satellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res 2000; 6:4782-8.
36. Blons H, Cabelguenne A, Carnot F, et al. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. Int J Cancer 1999; 84:410-5.
37. Irving JA, Bloodworth L, Bown NP, Case MC, Hogarth LA, Hall AG. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Res 2005; 65:3053-8.
38. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7.
39. Baker SJ, Preisinger AC, Jessup JM, et al. P53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50:7717-22.
40. Uchida K, Hayashi K, Kawakami K, et al. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004; 10:433-9.
41. Marsh S, Mcleod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 2001; 1:175-8.
42. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Campana D, Pui CH, Evans WE, Relling MV. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105:4752-8.
43. Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989; 244:207-11.
44. Tuzun E, Sharp AJ, Bailey JA, et al. Fine-scale structural variation of the human Genome. Nat Genet 2005; 37:727-32.
45. Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. Science 2004; 305:525-8.
46. Iafrate AJ, Feuk L, Rivera MN, et al. Detection of large-scale variation in the human genome. Nat Genet 2004; 36:949-51.
47. Lee C. Vive La difference! Nat Genet 2005; 37:660-1.
48. Van Ommen GJ. Frequency of new copy number variation in humans. Nat Genet 2005; 37:333-4.
49. Fredman D, White SJ, Potter S, Eichler EE, Den Dunnen JT, Brookes AJ. Complex SNP-related sequence variation in segmental genome duplications. Nat Genet 2004; 36:861-6.
50. Gut IG, Lathrop GM. Duplicating SNPs. Nat Genet 2004; 36:789-90.
51. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in nonsmall-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17:1786-93.
52. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: An update. Toxicology 2003; 193:3-34.
53. Boland CR, Thibodeau SN, Hamilton SR, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248-57.